CoreWeave, Inc. Class A Common Stock
CRWV is building a real AI infrastructure franchise, but at $87.85 the stock still overpays for growth that is being financed with $51.6B of debt, -$5.7B FCF, and a capital intensity that leaves little room for a clean equity outcome.
CoreWeave has built one of the few scaled AI infrastructure platforms that is actually delivering capacity into a supply-starved market. The demand data are hard to dismiss. Q2 revenue was $2.6B, up 112% y/y, backlog reached $104.2B, early-Q3 commitments added another $25B-plus, and management pushed FY2026 revenue guidance to $12.4B-$13.2B. This is not a speculative AI story with vague demand signals. It is a real business supplying scarce compute, raising prices by about 25% across SKUs in July, and expecting new-contract margins 5-10 points above recent quarters.
The problem is that the stock price already assumes that this operating momentum will flow through cleanly to equity value, and the capital structure says otherwise. CoreWeave finished FY2025 with -$5.7B of FCF, $51.6B of debt, 10.27x debt/equity, and 20.91x debt/EBITDA. Even after the operating inflection, management expects Q3 adjusted operating income of $200M-$260M but interest expense of $860M-$940M. That is the key mismatch in the story. The company is proving demand, pricing, and deployment. It is not yet proving that shareholders, rather than lenders and suppliers, will capture the economics.
The stock also is not obviously cheap on the metric the market is using. At 6.38x sales, CRWV trades roughly in line with the 6.3x peer average, despite a balance sheet and cash flow profile that are dramatically more fragile than software or infrastructure peers. The peer P/E average of 47.5x is not especially useful because CRWV still has negative earnings, and the peer set itself has wide dispersion of 6.2x, which weakens any relative valuation comfort. When valuation is this dependent on sales and future operating leverage, leverage quality matters more, not less.
What the case depends on now is narrow and measurable: first, whether the company can turn sold-out capacity and higher pricing into sustained low-teens operating margins by Q4 and beyond; second, whether capex intensity starts to fall relative to revenue; third, whether debt-funded expansion can continue without impairing the equity. If those three move in the right direction together, the stock can work. At $87.85, too much of that upside is already being paid for while the financing risk remains acute. That keeps the rating at SELL, not because the business lacks demand, but because the equity still looks overvalued relative to the balance-sheet burden required to chase it.
The 25% July price increase, sold-out capacity, and 5-10 point better margins on new contracts convert into faster operating earnings and reduce concern around the debt stack.
Revenue lands within the raised $12.4B-$13.2B guide, but leverage, dilution risk, and peer-dispersion concerns keep valuation anchored near the engine's sales-quality blend target.
Capex and interest stay elevated, pricing normalizes after the current GPU shortage, and the market rerates a 6.38x sales stock with $51.6B debt toward distressed-growth valuation.
Quant call (SELL) diverges from analyst consensus (Strong Buy: 10 buy / 5 hold / 1 sell) — resolve explicitly.
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
Forward earnings power is improving fast at the operating line, with FY2026 adjusted operating income guided to $960M-$1.15B and Q4 margins expected in the low teens, but equity value depends on what survives after nearly $1B of quarterly interest expense and giant capex. The trailing P/E is not usable because earnings are still negative, and the market is instead paying 6.38x sales, basically peer-like, for a company with far worse leverage than the peer set. The moat is real today, built on scarce GPU capacity, power procurement, and a sold-out AI cloud footprint, but over 3-5 years it is less secure if hyperscalers internalize more supply or if AI infrastructure pricing normalizes after the current shortage. AI remains a major secular tailwind for demand, especially inference, but the same AI boom is forcing a financing model so aggressive that equity holders may not capture as much of the value creation as the revenue backlog suggests.
- $12.4B-$13.2B FY2026 revenue guidance implies CoreWeave is still growing at extreme scale, but the market already capitalizes that growth at $52.7B.
- $51.6B total debt, 20.91x debt/EBITDA, and 0.46 current ratio make balance-sheet risk the central equity issue, not demand.
- Q3 interest expense of $860M-$940M against Q3 adjusted operating income of $200M-$260M shows operating progress is still being overwhelmed by financing costs.
- Q2 revenue was $2.6B, up 112% y/y and 24% q/q, with management raising FY2026 revenue guidance to $12.4B-$13.2B.
- Backlog reached $104.2B plus over $25B of early-Q3 commitments, and management said near-term capacity is effectively sold out.
- ~25% pricing increase across SKUs in July and management's view that margins on new contracts are 5-10 points above recent quarters support a real improvement in earnings power.
- 1.5 GW active power at Q2 end, heading to more than 1.85 GW by year-end 2026, shows capacity expansion is translating into deliverable supply, not just demand talk.
- FY2025 net margin was -25.7% and EPS was -$2.75, while even in Q3 CoreWeave expects $860M-$940M of interest expense, far above $200M-$260M of adjusted operating income.
- FCF was -$5.7B and the company is guiding to $11.5B-$13.5B of Q3 capex, which keeps the business dependent on continued external funding.
- Leverage is extreme at 10.27x debt/equity and 20.91x debt/EBITDA, with a thin 0.46 current ratio, limiting resilience if GPU demand, pricing, or deployment timing slips.
- The stock is already down 42.7% from the 52-week high and 4.5% below the 200-day average, but that drawdown alone does not make the valuation cheap when P/S is 6.38x versus a 6.3x peer average.
| Metric | Value | Context |
|---|---|---|
| Current price | $87.85 | Reference price for the rating and scenario analysis |
| Price target | $59.57 | -32.2% vs current, Medium confidence, basis: sales_quality_blend |
| FY2025 revenue | $5.1B | 644.4% YoY growth, showing exceptional scale-up |
| FY2025 EPS | -$2.75 | Negative earnings despite rapid revenue growth |
| FY2025 operating margin | 12.8% | Down from 16.9% in the prior FY |
| FY2025 net margin | -25.7% | Interest and capital structure still overwhelm operating gains |
| Valuation | P/S 6.38x, P/B 9.63x, market cap $52.7B | P/S is near the 6.3x peer average despite much weaker financial health |
| Leverage | Debt/Equity 10.27x, Debt/EBITDA 20.91x | Extreme leverage for a company still burning cash |
| Liquidity | Current ratio 0.46 | Thin near-term balance-sheet cushion |
| Cash flow and debt | FCF -$5.7B, total debt $51.6B | Expansion remains heavily externally funded |
| FY2026 guidance | Revenue $12.4B-$13.2B, adjusted operating income $960M-$1.15B | Raised after strong Q2 demand, pricing, and capacity additions |
| Price action | 52-week range $60.55-$153.20, now -42.7% vs high | Also -4.5% below 200-day average after volatile trading |
The biggest risk to the equity is financing strain, because Q3 interest expense of $860M-$940M and Q3 capex of $11.5B-$13.5B leave little margin for any slowdown in bookings, utilization, or capital markets access.
The next catalyst is the November 9, 2026 earnings report, especially whether Q3 operating income lands near the top of the $200M-$260M range and whether capex and interest begin to scale more slowly than revenue.
Ownership is concentrated enough to matter, with the top three institutions holding 36.0% and insiders at 10.9%. Short interest is elevated at 18.04%, or 61.3M shares, but days-to-cover is only 2, so this is not a classic hard-to-borrow squeeze setup. Options positioning is mildly supportive near spot because gamma is positive and zero-gamma sits at $86.24, close to the current price, which can dampen near-term volatility but does not change the fundamental leverage problem.
No geographic revenue split was provided in the supplied data, which limits visibility into concentration by region.
Core demand driver, supported by $104.2B backlog, sold-out near-term capacity, and Blackwell and Vera Rubin pricing at new highs.
Scaled from $1M to more than $100M ARR in a few months, with the first Omni deal expected to start scaling in 2027.
Management described this revenue as margin accretive, which matters because it can improve mix beyond raw GPU leasing.
CoreWeave raised FY26 outlook on surging demand, pricing, and capacity adds.
Management has executed well against the 2025 operating growth plan, but less cleanly on earnings consistency and capital intensity. At the 2025 Q1 call, CoreWeave guided FY2025 revenue to $4.9B-$5.1B and FY2025 actual revenue came in at $5.1B, so the company hit the high end of what it promised. It also said demand was accelerating and backed that with backlog of $25.9B and 420 MW active power, then expanded to $104.2B backlog and 1.5 GW active power by 2026 Q2, which supports management's credibility on demand and build delivery. The weaker part of the record is profit conversion and forecasting cadence: reported EPS has been uneven with 4 misses in the last 6 quarters, including misses of -419.3%, -16.4%, -78.1%, and -20.7% versus street estimates, and capex remains above plan at times, with Q2 2026 capex of $9.4B slightly above the high end of guidance. Direction has not changed materially, the company is still pursuing an all-in capacity build funded by debt, but the evidence says management is strong at selling and deploying infrastructure and less proven at delivering smooth earnings to equity holders.
Our disciplined execution and the momentum we are seeing across our customer base gives us confidence in raising our full year 2026 revenue guidance to $12.4 billion to $13.2 billion and adjusted operating income to $960 million to $1.15 billion.
We expect Q3 revenue to be in the range of $3.45 billion to $3.6 billion. We expect Q3 adjusted operating income of $200 million to $260 million as margins continue to sequentially expand reaching low teens in Q4.
Q2 was an exceptional quarter for CoreWeave. We outperformed our plan across the board with the operating leverage we have been building beginning to show up clearly in our results.
this operating margin improvement came before our July pricing changes which included an approximately 25% increase across SKUs in response to the current demand environment and the increasing ROI our customers are observing from their investments in the CoreWeave platform as they shift to inference.
Our near-term capacity remains effectively sold out. That is translating into signed commitments on increasingly favorable terms from a broadening set of customers and is positioning CoreWeave to gain market share for years to come.
CoreWeave's moat is built on scarce assets that are hard to replicate quickly: access to advanced GPUs, contracted power, deployed data-center capacity, and a delivery engine that took active power from 420 MW around the 2025 Q1 call to 1.5 GW by 2026 Q2. That matters in an AI market where customers want capacity now, not in two years. The durability is mixed: strong over the next 12-24 months while capacity is constrained and the company is effectively sold out, less certain over 3-5 years if hyperscalers absorb supply internally or if infrastructure becomes less scarce and more price competitive.
Capital allocation is aggressively expansionary. There are no buybacks and no dividend, which is appropriate given the balance sheet, but it is being offset by extraordinary infrastructure spend, including $9.4B of Q2 capex and $11.5B-$13.5B guided for Q3. That spend is tied to real demand and backlog, but with FCF at -$5.7B and debt already at $51.6B, discipline has to be judged not by growth alone but by whether returns on new capacity remain well above the rising cost of capital.
CRWV is a real AI infrastructure winner, but the stock still rates SELL because the balance sheet and funding burden are too heavy for a peer-like sales multiple. The business is headed in the right direction operationally, with backlog, pricing, and capacity all improving, yet the equity remains subordinate to $51.6B of debt, giant capex, and quarterly interest expense that still outstrips operating income. A better entry would require either a much lower stock price or clear proof that capex intensity and financing costs are finally falling relative to revenue. The rating would change if CoreWeave shows sustained positive free cash flow or a materially safer leverage path without sacrificing growth.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. CRWV rates a SELL at Medium conviction. The business is scaling fast, with FY2026 revenue guided to $12.4B-$13.2B, $104.2B backlog, and pricing power that is real, but the equity sits behind an unusually levered balance sheet, Q3 interest expense of $860M-$940M, and capex that remains enormous at $11.5B-$13.5B for just one quarter. With the stock still trading at 6.38x sales, roughly in line with peers despite much weaker financial health and far higher leverage, the setup remains unfavorable.
Investment Thesis
CoreWeave has built one of the few scaled AI infrastructure platforms that is actually delivering capacity into a supply-starved market. The demand data are hard to dismiss. Q2 revenue was $2.6B, up 112% y/y, backlog reached $104.2B, early-Q3 commitments added another $25B-plus, and management pushed FY2026 revenue guidance to $12.4B-$13.2B. This is not a speculative AI story with vague demand signals. It is a real business supplying scarce compute, raising prices by about 25% across SKUs in July, and expecting new-contract margins 5-10 points above recent quarters.
The problem is that the stock price already assumes that this operating momentum will flow through cleanly to equity value, and the capital structure says otherwise. CoreWeave finished FY2025 with -$5.7B of FCF, $51.6B of debt, 10.27x debt/equity, and 20.91x debt/EBITDA. Even after the operating inflection, management expects Q3 adjusted operating income of $200M-$260M but interest expense of $860M-$940M. That is the key mismatch in the story. The company is proving demand, pricing, and deployment. It is not yet proving that shareholders, rather than lenders and suppliers, will capture the economics.
The stock also is not obviously cheap on the metric the market is using. At 6.38x sales, CRWV trades roughly in line with the 6.3x peer average, despite a balance sheet and cash flow profile that are dramatically more fragile than software or infrastructure peers. The peer P/E average of 47.5x is not especially useful because CRWV still has negative earnings, and the peer set itself has wide dispersion of 6.2x, which weakens any relative valuation comfort. When valuation is this dependent on sales and future operating leverage, leverage quality matters more, not less.
What the case depends on now is narrow and measurable: first, whether the company can turn sold-out capacity and higher pricing into sustained low-teens operating margins by Q4 and beyond; second, whether capex intensity starts to fall relative to revenue; third, whether debt-funded expansion can continue without impairing the equity. If those three move in the right direction together, the stock can work. At $87.85, too much of that upside is already being paid for while the financing risk remains acute. That keeps the rating at SELL, not because the business lacks demand, but because the equity still looks overvalued relative to the balance-sheet burden required to chase it.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $87.85 | Reference price for the rating and scenario analysis |
| Price target | $59.57 | -32.2% vs current, Medium confidence, basis: sales_quality_blend |
| FY2025 revenue | $5.1B | 644.4% YoY growth, showing exceptional scale-up |
| FY2025 EPS | -$2.75 | Negative earnings despite rapid revenue growth |
| FY2025 operating margin | 12.8% | Down from 16.9% in the prior FY |
| FY2025 net margin | -25.7% | Interest and capital structure still overwhelm operating gains |
| Valuation | P/S 6.38x, P/B 9.63x, market cap $52.7B | P/S is near the 6.3x peer average despite much weaker financial health |
| Leverage | Debt/Equity 10.27x, Debt/EBITDA 20.91x | Extreme leverage for a company still burning cash |
| Liquidity | Current ratio 0.46 | Thin near-term balance-sheet cushion |
| Cash flow and debt | FCF -$5.7B, total debt $51.6B | Expansion remains heavily externally funded |
| FY2026 guidance | Revenue $12.4B-$13.2B, adjusted operating income $960M-$1.15B | Raised after strong Q2 demand, pricing, and capacity additions |
| Price action | 52-week range $60.55-$153.20, now -42.7% vs high | Also -4.5% below 200-day average after volatile trading |
Financial Strength
The operating engine is clearly strengthening, but the balance sheet remains the governing fact. CoreWeave is showing real EBITDA generation, with Q2 adjusted EBITDA of $1.5B and a 58.1% margin, and management expects sequential margin expansion into Q4. That is the good news. The problem is that this sits alongside $51.6B of debt, 20.91x debt/EBITDA, a 0.46 current ratio, and -$5.7B FCF, which means the business is not self-funding despite revenue hypergrowth. Financially, this is not weak because demand is weak. It is weak because the model is absorbing huge capex and interest loads at the same time, which leaves equity holders exposed to any slip in pricing, utilization, or capital availability.
Competitive Position
CoreWeave's moat is built on scarce assets that are hard to replicate quickly: access to advanced GPUs, contracted power, deployed data-center capacity, and a delivery engine that took active power from 420 MW around the 2025 Q1 call to 1.5 GW by 2026 Q2. That matters in an AI market where customers want capacity now, not in two years. The durability is mixed: strong over the next 12-24 months while capacity is constrained and the company is effectively sold out, less certain over 3-5 years if hyperscalers absorb supply internally or if infrastructure becomes less scarce and more price competitive.
Management & Guidance
Management's current guidance is unambiguously strong on demand. The company raised FY2026 revenue to $12.4B-$13.2B and adjusted operating income to $960M-$1.15B, while guiding Q3 revenue to $3.45B-$3.60B and Q3 adjusted operating income to $200M-$260M. The call support behind that guide is solid: $104.2B backlog, sold-out near-term capacity, a 25% July SKU price increase, and higher-margin new contracts. Credibility is mixed, not poor. Management has been right about demand acceleration and capacity build-out, but the reported EPS record is uneven with multiple misses and capex can run above plan, so the guide is credible on revenue direction and less proven on what ultimately drops to the bottom line.
Segment Analysis
- Geography (Not disclosed): No geographic revenue split was provided in the supplied data, which limits visibility into concentration by region.
- AI cloud infrastructure and compute (Majority of revenue): Core demand driver, supported by $104.2B backlog, sold-out near-term capacity, and Blackwell and Vera Rubin pricing at new highs.
- Managed inference (ARR >$100M): Scaled from $1M to more than $100M ARR in a few months, with the first Omni deal expected to start scaling in 2027.
- Non-GPU services (ARR >$400M): Management described this revenue as margin accretive, which matters because it can improve mix beyond raw GPU leasing.
Capital Allocation
Capital allocation is aggressively expansionary. There are no buybacks and no dividend, which is appropriate given the balance sheet, but it is being offset by extraordinary infrastructure spend, including $9.4B of Q2 capex and $11.5B-$13.5B guided for Q3. That spend is tied to real demand and backlog, but with FCF at -$5.7B and debt already at $51.6B, discipline has to be judged not by growth alone but by whether returns on new capacity remain well above the rising cost of capital.
Management Execution & Track Record
Management has executed well against the 2025 operating growth plan, but less cleanly on earnings consistency and capital intensity. At the 2025 Q1 call, CoreWeave guided FY2025 revenue to $4.9B-$5.1B and FY2025 actual revenue came in at $5.1B, so the company hit the high end of what it promised. It also said demand was accelerating and backed that with backlog of $25.9B and 420 MW active power, then expanded to $104.2B backlog and 1.5 GW active power by 2026 Q2, which supports management's credibility on demand and build delivery. The weaker part of the record is profit conversion and forecasting cadence: reported EPS has been uneven with 4 misses in the last 6 quarters, including misses of -419.3%, -16.4%, -78.1%, and -20.7% versus street estimates, and capex remains above plan at times, with Q2 2026 capex of $9.4B slightly above the high end of guidance. Direction has not changed materially, the company is still pursuing an all-in capacity build funded by debt, but the evidence says management is strong at selling and deploying infrastructure and less proven at delivering smooth earnings to equity holders.
Positioning & Flows
Ownership is concentrated enough to matter, with the top three institutions holding 36.0% and insiders at 10.9%. Short interest is elevated at 18.04%, or 61.3M shares, but days-to-cover is only 2, so this is not a classic hard-to-borrow squeeze setup. Options positioning is mildly supportive near spot because gamma is positive and zero-gamma sits at $86.24, close to the current price, which can dampen near-term volatility but does not change the fundamental leverage problem.
Bull Case
- Q2 revenue was $2.6B, up 112% y/y and 24% q/q, with management raising FY2026 revenue guidance to $12.4B-$13.2B.
- Backlog reached $104.2B plus over $25B of early-Q3 commitments, and management said near-term capacity is effectively sold out.
- ~25% pricing increase across SKUs in July and management's view that margins on new contracts are 5-10 points above recent quarters support a real improvement in earnings power.
- 1.5 GW active power at Q2 end, heading to more than 1.85 GW by year-end 2026, shows capacity expansion is translating into deliverable supply, not just demand talk.
Bear Case
- FY2025 net margin was -25.7% and EPS was -$2.75, while even in Q3 CoreWeave expects $860M-$940M of interest expense, far above $200M-$260M of adjusted operating income.
- FCF was -$5.7B and the company is guiding to $11.5B-$13.5B of Q3 capex, which keeps the business dependent on continued external funding.
- Leverage is extreme at 10.27x debt/equity and 20.91x debt/EBITDA, with a thin 0.46 current ratio, limiting resilience if GPU demand, pricing, or deployment timing slips.
- The stock is already down 42.7% from the 52-week high and 4.5% below the 200-day average, but that drawdown alone does not make the valuation cheap when P/S is 6.38x versus a 6.3x peer average.
Valuation & Price Target
Engine price target $59.57 (-32.2% vs current), Medium confidence.
- P/S Multiple: $49.5 (45% weight)
- Quality-adjusted: $82.23 (20% weight)
The rating aligns with the quant baseline SELL. The engine's $59.57 price target already blends a much higher quality-adjusted value of $82.23 with a lower P/S-based value of $49.5, and that quality uplift still only gets to a target 32.2% below the current price. That conclusion fits the fundamental picture: P/S of 6.38x is only about in line with the 6.3x peer average, yet CoreWeave carries $51.6B of debt, 20.91x debt/EBITDA, 0.46 current ratio, and -$5.7B FCF, which are much worse than what a peer-like multiple usually deserves. The bullish sell-side consensus is low signal here and likely reflects excitement around AI demand, backlog, and pricing, all of which are real, but it does not erase the fact that the equity sits behind a financing structure that still dominates the valuation case.
Risk Assessment
Risk score 59/100 (Moderate). The biggest risk to the equity is financing strain, because Q3 interest expense of $860M-$940M and Q3 capex of $11.5B-$13.5B leave little margin for any slowdown in bookings, utilization, or capital markets access.
The Bottom Line
CRWV is a real AI infrastructure winner, but the stock still rates SELL because the balance sheet and funding burden are too heavy for a peer-like sales multiple. The business is headed in the right direction operationally, with backlog, pricing, and capacity all improving, yet the equity remains subordinate to $51.6B of debt, giant capex, and quarterly interest expense that still outstrips operating income. A better entry would require either a much lower stock price or clear proof that capex intensity and financing costs are finally falling relative to revenue. The rating would change if CoreWeave shows sustained positive free cash flow or a materially safer leverage path without sacrificing growth.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr